Latest:
Code Overload
The ICD-9 medical coding system we’ve all relied on for decades will soon change.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jonathan Brammer, MD
Latest:
Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL
Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).
Jonathan D. Schoenfeld, MD, MPhil, MPH
Latest:
Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer
Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.
Jonathan D. Tward, MD, PhD
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations
Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate
cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Jonathan E. Brammer, MD
Latest:
Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma
Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.
Jonathan L. Wright, MD, MS, FACS
Latest:
Dr. Wright on Frontline Considerations in Locally Advanced Bladder Cancer
Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.
Jonathan Ledermann, MD, PhD
Latest:
Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer
Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.